5
Maestros Mediline Systems Ltd
501209 BSE
Maestros Mediline Systems Ltd
BSE: 501209
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Maestros Mediline Systems Ltd insights
29 extracted metrics + investor summaries across FY08–FY16.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -57.8% over past five years.
- Company has high debtors of 1,251 days.
Growth Rate
Revenue Growth
-87.00% →
Net Income Growth
87.00% →
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-
Quarterly Results
| Jun 2013 | Sep 2013 | Dec 2013 | Jun 2014 | Sep 2014 | |
|---|---|---|---|---|---|
| Sales | 3.44 | 1.97 | 0.26 | 1.09 | 1.07 |
| Expenses | 4.41 | 0.05 | 0.36 | 0.58 | 1.76 |
| Operating Profit | -0.97 | 1.92 | -0.1 | 0.51 | -0.69 |
| OPM % | -28.2% | 97.46% | -38.46% | 46.79% | -64.49% |
| Other Income | 0 | 0 | 0.02 | 0 | 0 |
| Interest | 0.18 | 0.01 | 0 | 0 | 0.01 |
| Depreciation | 0.48 | 0.51 | 0.48 | 0.18 | 0.19 |
| PBT | -1.63 | 1.4 | -0.56 | 0.33 | -0.89 |
| Tax % | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -1.63 | 1.4 | -0.57 | 0.32 | -0.89 |
| EPS in Rs | -3.7 | 3.18 | -1.3 | 0.73 | -2.02 |
Profit & Loss
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.81 | 29.23 | 30.05 | 41.78 | 42.4 | 21.75 | 7.02 | 4.23 | 0.56 |
| Expenses | 30.28 | 25.66 | 26.06 | 33.48 | 34.79 | 31.93 | 20.46 | 25.74 | 2.99 |
| Operating Profit | 3.53 | 3.57 | 3.99 | 8.3 | 7.61 | -10.18 | -13.44 | -21.51 | -2.43 |
| OPM % | 10.44% | 12.21% | 13.28% | 19.87% | 17.95% | -46.8% | -191.45% | -508.51% | -433.93% |
| Other Income | 0.27 | 0.59 | 0.94 | 0.8 | 0.23 | 0.76 | -0.88 | 0.04 | 0.14 |
| Interest | 1.59 | 1.84 | 2.39 | 2.95 | 4.04 | 5.38 | 0.37 | 0.03 | 0.02 |
| Depreciation | 1.27 | 1.26 | 1.76 | 2.37 | 1.86 | 2.06 | 1 | 0.79 | 0.7 |
| PBT | 0.94 | 1.06 | 0.78 | 3.78 | 1.94 | -16.86 | -15.69 | -22.29 | -3.01 |
| Tax % | 44.68% | 75.47% | 23.08% | 2.91% | -7.73% | -7.41% | 0% | 0% | 0% |
| Net Profit | 0.52 | 0.26 | 0.6 | 3.67 | 2.08 | -15.61 | -15.69 | -22.29 | -3 |
| EPS in Rs | — | 0.59 | 1.36 | 8.34 | 4.73 | -35.48 | -35.66 | -50.66 | -6.82 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.55 | 4.42 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 | 4.37 |
| Reserves | 30.89 | 30.77 | 31.23 | 34.97 | 13.15 | -2.56 | -18.39 | -41.46 | -44.46 |
| Borrowings | 4.39 | 7.79 | 7.5 | 11.72 | 38.96 | 49.68 | 51.06 | 54.1 | 54.37 |
| Other Liabilities | 18.6 | 23.58 | 26 | 24.39 | 21.25 | 22.43 | 20.16 | 5.91 | 7.79 |
| Total Liabilities | 58.43 | 66.56 | 69.1 | 75.45 | 77.73 | 73.92 | 57.2 | 22.92 | 22.07 |
| Fixed Assets | 23.17 | 28.04 | 28.19 | 31.14 | 15.62 | 15.28 | 13.45 | 11.89 | 11.19 |
| CWIP | 0.18 | 0.36 | 0 | 0 | 7.4 | 0 | 0 | 0 | 0 |
| Investments | 3.89 | 0.31 | 0.31 | 0.81 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 31.19 | 37.85 | 40.6 | 43.5 | 54.71 | 58.64 | 43.75 | 11.03 | 10.88 |
| Total Assets | 58.43 | 66.56 | 69.1 | 75.45 | 77.73 | 73.92 | 57.2 | 22.92 | 22.07 |
Cash Flow
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 12.76 | 7.28 | 3.24 | 2.84 | -7.5 | -6.77 | -0.45 | -0.27 | 0.09 |
| Investing | -4.82 | -2.58 | -1.55 | -5.98 | -14.89 | 1.08 | 0.94 | -0.38 | 0.05 |
| Financing | -7.48 | 0.98 | -2.88 | 1.28 | 23.8 | 2.16 | -0.26 | -0.14 | 0.04 |
| Net Cash Flow | 0.46 | 5.68 | -1.19 | -1.86 | 1.41 | -3.53 | 0.22 | -0.79 | 0.18 |
| Free Cash Flow | 12.78 | 7.28 | 3.24 | 2.86 | -22.48 | -6.77 | -0.45 | -0.27 | 0.09 |
| CFO/OP | 361 | 204 | 81 | 34 | -99 | 66 | 3 | 1 | -4 |
Ratios
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 152 | 138 | 152 | 127 | 214 | 393 | 1,302 | 225 | 1,251 |
| Inventory Days | 159 | 236 | 273 | 241 | 262 | 241 | 66.54 | 40.16 | 69.3 |
| Days Payable | 115 | 180 | 240 | 154 | 209 | 180 | 257 | 129 | 1,686 |
| Cash Conversion Cycle | 196 | 193 | 186 | 214 | 268 | 454 | 1,112 | 136 | -366 |
| Working Capital Days | 138 | 120 | 139 | 163 | 259 | 579 | 1,132 | 319 | 1,004 |
| ROCE % | — | 7% | 7.37% | 14.32% | 11.12% | -21.27% | -32.62% | -82.37% | -19.11% |
Documents
4
Results - Revised Audited Financial Results For March 2025
10h - Revised FY2025 audited results; auditor disclaimer; cash loss ₹1,665.68L; borrowings ₹5,167.61L; tax demands ₹5,150.47L. 10h - Revised FY2025 audited results; auditor disclaimer; cash loss ₹1,665.68L; borrowings ₹5,167.61L; tax demands ₹5,150.47L.
Frequently Asked Questions about Maestros Mediline Systems Ltd
What does Maestros Mediline Systems Ltd do?
Maestros is India's leading medical diagnostic equipment and services organizations, which focuses on empowering medical professionals and institutions, that treat cardiac, gynecology and critical care patients across the country.
Where is Maestros Mediline Systems Ltd (501209) listed?
Maestros Mediline Systems Ltd is listed on the Indian stock exchanges. It is listed on BSE: 501209. You can view its live share price, financials, and ratios on Tapetide.
How can I research Maestros Mediline Systems Ltd on Tapetide?
On Tapetide, you can view Maestros Mediline Systems Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Maestros is India's leading medical diagnostic equipment and services organizations, which focuses on empowering medical professionals and institutions, that treat cardiac, gynecology and critical care patients across the country.